RU2017115932A - T-клеточные рецепторы - Google Patents
T-клеточные рецепторы Download PDFInfo
- Publication number
- RU2017115932A RU2017115932A RU2017115932A RU2017115932A RU2017115932A RU 2017115932 A RU2017115932 A RU 2017115932A RU 2017115932 A RU2017115932 A RU 2017115932A RU 2017115932 A RU2017115932 A RU 2017115932A RU 2017115932 A RU2017115932 A RU 2017115932A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid residues
- sequence
- seq
- tcr
- Prior art date
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims 34
- 108091008874 T cell receptors Proteins 0.000 title claims 33
- 125000000539 amino acid group Chemical group 0.000 claims 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 4
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims 3
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims 3
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims 3
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 108010059255 MAGE-A10 antigen Proteins 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061248P | 2014-10-08 | 2014-10-08 | |
| GB1417803.2 | 2014-10-08 | ||
| GBGB1417803.2A GB201417803D0 (en) | 2014-10-08 | 2014-10-08 | T cell receptors |
| US62/061,248 | 2014-10-08 | ||
| PCT/GB2015/052938 WO2016055785A1 (en) | 2014-10-08 | 2015-10-08 | T cell receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017115932A true RU2017115932A (ru) | 2018-11-12 |
| RU2017115932A3 RU2017115932A3 (enExample) | 2019-04-05 |
Family
ID=51947049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017115932A RU2017115932A (ru) | 2014-10-08 | 2015-10-08 | T-клеточные рецепторы |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11203627B2 (enExample) |
| EP (1) | EP3204409A1 (enExample) |
| JP (2) | JP6751391B2 (enExample) |
| KR (1) | KR20170092535A (enExample) |
| CN (1) | CN107001443A (enExample) |
| AU (2) | AU2015329783A1 (enExample) |
| BR (1) | BR112017007202A2 (enExample) |
| CA (1) | CA2963332A1 (enExample) |
| GB (1) | GB201417803D0 (enExample) |
| IL (1) | IL251524B (enExample) |
| MX (1) | MX2017004559A (enExample) |
| NZ (1) | NZ731571A (enExample) |
| RU (1) | RU2017115932A (enExample) |
| SG (1) | SG11201701983WA (enExample) |
| WO (1) | WO2016055785A1 (enExample) |
| ZA (1) | ZA201701823B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| KR102523449B1 (ko) | 2016-04-08 | 2023-04-19 | 어댑티뮨 리미티드 | T 세포 수용체 |
| GB201616238D0 (en) * | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| MA50188A (fr) | 2017-09-22 | 2021-06-02 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques bispécifiques |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| CN109879957B (zh) * | 2017-12-06 | 2022-03-18 | 香雪生命科学技术（广东）有限公司 | 针对prame的高亲和力t细胞受体 |
| EP3775238A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2020156405A1 (en) * | 2019-01-28 | 2020-08-06 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel bispecific cd3/cd20 polypeptide complexes |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| EP3997116A1 (en) * | 2019-07-09 | 2022-05-18 | Medigene Immunotherapies GmbH | Magea10 specific t cell receptors and their use |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| WO2022022696A1 (zh) * | 2020-07-30 | 2022-02-03 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力tcr |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240100162A1 (en) * | 2020-12-22 | 2024-03-28 | Amgen Inc. | Mage-b2-specific t-cell receptors |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117003855B (zh) * | 2023-09-20 | 2024-02-23 | 广州市老人院 | 一种t细胞受体及其应用 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN121779537A (zh) * | 2026-03-06 | 2026-04-03 | 北京立康生命科技有限公司 | 一种针对mage肽的特异性t细胞受体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| JP2007032255A (ja) | 2005-06-24 | 2007-02-08 | Tokai Rika Co Ltd | 車両用信号発信装置 |
| CN101287831B (zh) * | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| SG177025A1 (en) * | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
| CN103097407A (zh) * | 2010-07-28 | 2013-05-08 | 英美偌科有限公司 | T细胞受体 |
| AU2011304728A1 (en) * | 2010-09-20 | 2013-03-14 | Biontech Ag | Antigen-specific T cell receptors and T cell epitopes |
| CA2822938A1 (en) | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
| CA3114877C (en) * | 2011-09-15 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| WO2013057586A1 (en) * | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| HK1212237A1 (en) * | 2012-08-31 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| HUE050390T2 (hu) * | 2013-01-29 | 2020-11-30 | Max Delbrueck Centrum Fuer Molekulare Medizin Mdc | MAGE-A 1-t felismerõ nagy aviditású kötõ molekulák |
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| EP3519433A1 (en) * | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
-
2014
- 2014-10-08 GB GBGB1417803.2A patent/GB201417803D0/en not_active Ceased
-
2015
- 2015-10-08 WO PCT/GB2015/052938 patent/WO2016055785A1/en not_active Ceased
- 2015-10-08 JP JP2017519573A patent/JP6751391B2/ja not_active Expired - Fee Related
- 2015-10-08 CN CN201580054549.1A patent/CN107001443A/zh active Pending
- 2015-10-08 EP EP15782040.8A patent/EP3204409A1/en not_active Ceased
- 2015-10-08 SG SG11201701983WA patent/SG11201701983WA/en unknown
- 2015-10-08 CA CA2963332A patent/CA2963332A1/en not_active Abandoned
- 2015-10-08 MX MX2017004559A patent/MX2017004559A/es unknown
- 2015-10-08 RU RU2017115932A patent/RU2017115932A/ru unknown
- 2015-10-08 KR KR1020177012435A patent/KR20170092535A/ko not_active Ceased
- 2015-10-08 AU AU2015329783A patent/AU2015329783A1/en not_active Abandoned
- 2015-10-08 NZ NZ731571A patent/NZ731571A/en not_active IP Right Cessation
- 2015-10-08 BR BR112017007202-5A patent/BR112017007202A2/pt not_active IP Right Cessation
-
2017
- 2017-03-14 ZA ZA2017/01823A patent/ZA201701823B/en unknown
- 2017-04-03 IL IL251524A patent/IL251524B/en unknown
- 2017-04-05 US US15/480,103 patent/US11203627B2/en not_active Expired - Fee Related
-
2020
- 2020-04-10 JP JP2020070831A patent/JP2020127406A/ja not_active Ceased
- 2020-05-15 AU AU2020203201A patent/AU2020203201A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6751391B2 (ja) | 2020-09-02 |
| BR112017007202A2 (pt) | 2018-03-06 |
| KR20170092535A (ko) | 2017-08-11 |
| IL251524A0 (en) | 2017-05-29 |
| US20170218043A1 (en) | 2017-08-03 |
| EP3204409A1 (en) | 2017-08-16 |
| CN107001443A (zh) | 2017-08-01 |
| RU2017115932A3 (enExample) | 2019-04-05 |
| US20180208638A9 (en) | 2018-07-26 |
| AU2020203201A1 (en) | 2020-06-04 |
| JP2017533698A (ja) | 2017-11-16 |
| SG11201701983WA (en) | 2017-04-27 |
| CA2963332A1 (en) | 2016-04-14 |
| ZA201701823B (en) | 2019-06-26 |
| MX2017004559A (es) | 2018-02-23 |
| AU2015329783A1 (en) | 2017-05-25 |
| JP2020127406A (ja) | 2020-08-27 |
| GB201417803D0 (en) | 2014-11-19 |
| IL251524B (en) | 2021-09-30 |
| WO2016055785A1 (en) | 2016-04-14 |
| US11203627B2 (en) | 2021-12-21 |
| NZ731571A (en) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533698A5 (enExample) | ||
| HRP20191371T1 (hr) | T-stanični receptori | |
| JP2020127406A5 (enExample) | ||
| RU2018138837A (ru) | Т-клеточные рецепторы | |
| BR112018070741A2 (pt) | receptor de células t (tcr), tcr que se liga a um complexo hla-a*02, molécula de fusão a anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou projetada, composição farmacêutica, método de tratamento de um indivíduo humano em necessidade deste, formulação injetável para administração a um indivíduo humano, e método de produção de um tcr | |
| IL262128B1 (en) | T cell receptors | |
| HRP20190472T4 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| HRP20240998T1 (hr) | T stanični receptori | |
| RU2018138836A (ru) | Т-клеточные рецепторы | |
| FI3433270T3 (fi) | T-solureseptoreita | |
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| CN107001443A (zh) | T细胞受体 | |
| JP2019517790A5 (enExample) | ||
| EA201892217A1 (ru) | Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII | |
| HRP20221375T1 (hr) | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka | |
| IL314832A (en) | Hiv-specific binding molecules and tcr | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| KR20220015376A (ko) | Hbv 외피 단백질에 특이적인 결합 분자 | |
| Huen et al. | The Drosophila Ret gene is transcribed in multiple alternatively spliced forms | |
| RU2022116808A (ru) | Т-клеточные рецепторы | |
| HK1222338B (en) | T cell receptors |